Titan Pharmaceuticals (OTCQB:TTNPD) has received approval to list its common stock on the NASDAQ Capital Market, effective at the opening on Monday, Oct.12, under the symbol TTNP.
“Uplisting to the NASDAQ Capital Market comes at an important time of growth for Titan, as we await potential approval of Probuphine in the first quarter next year and expand our pipeline of product candidates based on our ProNeura long-term, continuous drug delivery technology,” Titan president, Sunil Bhonsle, said in a statement.
“As a company listed on NASDAQ, Titan will gain greater visibility across a broader range of professional and institutional investors, and potentially generate more value for all of our shareholders,” he added.
Before trading on NASDAQ begins, Titan’s common stock will continue to be quoted on the OTCQB under the symbol TTNPD
